Waters acquires Halo Labs

Waters (WAT) announced that it has acquired Halo Labs, an innovator of specialized imaging technologies to detect, identify, and count interfering materials in therapeutic products, such as cell, protein, and gene therapies. The Aura platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy, detecting these translucent process impurities that are currently undetectable by standard methods. By acquiring this innovative company, Waters will be able to integrate this emerging technology into new and existing large molecule development and QA/QC, giving a key value-add to customers while accelerating the Company’s growth into analytical and bioprocessing testing for large molecule therapies. Today’s acquisition of Halo Labs is expected to have a negligible impact on the Company’s income statement over the following 12 months.